Drugs / SXL01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02866916 | Sep 2017 → Jun 2020 | castration-resistant prostate carcinoma | Institut Claudius Regaud | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SXL01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02866916 ↗ |
| Modality | Small interfering RNA (siRNA) | “a synthetic small interfering ribonucleic acid (RNA)” NCT02866916 ↗ |
| Route | Subcutaneous | “Treatment will be administered continuously over 24h through the subcutaneous route.” NCT02866916 ↗ |
| Target | AR | “targeting the androgen receptor messenger RNA (mRNA)” NCT02866916 ↗ |